Axios

Moderna and Merck shares soar on mRNA cancer vaccine

Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after

By Axios

1 min read
Moderna and Merck shares soar on mRNA cancer vaccine
Moderna and Merck shares soar on mRNA cancer vaccine

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Business & Leadership

Related Insights